Abstract P6-05-01: Triple Negative Breast Cancer in Korea — Distinct Biology with Different Impact of Prognostic Factors on Survival

e22158 Background: Triple negative breast cancer (TNBC) is generally considered as a poorer prognostic subgroup, with a propensity for earlier relapse and visceral involvement. The aim of this study is to evaluate the outcome of non-metastatic TNBC patients in a National registry setting and identify clinical and pathologic variables associated with survival. Methods: From a retrospective registry cohort of 296 TNBC patients treated and followed between 1993–2007, we identified 248 patients with early stage disease, with follow-up of at least 12 months. The prognostic impact of several clinical variables were evaluated by the Kaplan-Meier and Cox multivariate anayses. Results: Median age was 48. The majority of the patient group had invasive ductal carcinoma (n:204, 82.3%). Distribution by stage was as follows: stage 1: 49 (19.8%), st 2: 125 (50.4%), st 3: 69 (27.8%). Excluding 11 patients, all had received adjuvant chemotherapy. 5 year overall survival (OS) and disease-free survival (DFS) rates were 84±2.7 % and 69±3.3%, respectively. Median survival after initial recurrence was 20 months. Sites of relapse were as follows: lung: 26 (36.1%), liver:8 (11.1%), brain: 8 (11.1%), bone: 14 (19.4%), skin/lymphatic: 7 (9.7%). Univariate analysis revealed locally advanced disease (p:0.0001), larger tumor size (p:0.004), nodal positivity (p<0.00001), and extent of nodal involvement as significant factors for DFS; whereas, locally advanced disease (p:0.0099) and extent of nodal involvement (p:0.018) were identified as prognostic factors with an impact on OS. Multivariate analysis revealed locally advanced disease (HR: 3.3, p:0.02, 95% CI: 0.14–0.64) and extent of nodal involvement (HR:4.3, p:0.033, 95% CI: 0.059–0.88) as significant independent prognostic factors for DFS and OS, respectively. Conclusions: The outcome of patients with TNBC in this National registry cohort is comparable to other subsets with similar prognostic features and do not support the generally accepted notion that TNBC entails poor prognosis. It may be speculated that there may be inherent ethnic differences leading to distinctive tumor behaviour. Further translational research is required to identify molecular prognostic groups within the TN subset. No significant financial relationships to disclose.

Download Full-text

41 Prognostic factors and survival outcome in triple negative breast cancer patients in routine clinical practice in Slovenia

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)70072-0 ◽

2010 ◽

Vol 8 (3) ◽

pp. 70

Author(s):

T. Ovcaricek ◽

E. Matos ◽

M. Ravnik ◽

S. Grazio Frkovic ◽

B. Mozina ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Clinical Practice ◽

Cancer Patients ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Survival Outcome ◽

Routine Clinical Practice ◽

Breast Cancer Patients

Download Full-text

Prognostic factors for early relapse in non-metastatic triple negative breast cancer — real world data

Reports of Practical Oncology & Radiotherapy ◽

10.5603/rpor.a2021.0073 ◽

2021 ◽

Author(s):

Rita Félix Soares ◽

Ana Rita Garcia ◽

Ana Raquel Monteiro ◽

Filipa Macedo ◽

Tatiana Cunha Pereira ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Triple Negative Breast Cancer ◽

Real World ◽

Triple Negative ◽

Real World Data ◽

Early Relapse ◽

World Data

Download Full-text

Relationship of ER, PR, HER2 / neu with Other Prognostic Factors in Breast Cancer along with the Role of Androgen Receptor in Triple Negative Breast Cancer

Journal of Evolution of Medical and Dental Sciences ◽

10.14260/jemds/2021/116 ◽

2021 ◽

Vol 10 (8) ◽

pp. 536-540

Author(s):

Arshi Khan ◽

Reeni Malik ◽

Pramila Jain ◽

Deepshikha Verma ◽

Vedanti Newasker

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Androgen Receptor ◽

Triple Negative Breast Cancer ◽

Oestrogen Receptor ◽

Triple Negative ◽

Receptor Expression ◽

Proliferation Index ◽

Lymph Node Status ◽

Significant Information

BACKGROUND Understanding various risk factors associated with breast cancer can help in early identification & prompt treatment of patients with breast cancer. Apart from clinical parameters like age, disease presentation and menopausal status, important prognostic indicators in histopathology are size and extent of tumour, histologic type,histologic grade and lymph node status. Also, there are other factors which are not only predictive of outcome, but also direct therapies against particular molecular targets. These factors are oestrogen receptor (ER) status, progesterone receptor (PR) status, HER2 / neu status, Ki-67 proliferation index & androgen receptor (AR) status. We wanted to analyse various hormone receptors & their correlation with prognostic factors. In addition, androgen receptor expression is also studied in triple negative breast cancer cases. METHODS The study included 50 cases over a period of 18 months from January 2018 to June 2019 received in the Department of Pathology, Gandhi Medical College, Bhopal, India. These cases were subjected to histopathological & immunohistochemistry (IHC) evaluation. RESULTS Among the 50 cases studied, the most common subtype was infiltrating ductal carcinoma (NOS - no special type, 84 %). Majority of patients were ER, PR, HER2 / neu negative (48 %) and among those triple negative cases, 25 % of cases were androgen receptor positive. CONCLUSIONS Expression of the hormone receptor (ER and PR) and HER2 status may provide significant information in directing patient management. Since traditional pathological methods and IHC remain standard for guiding the use of treatment, clinicians may be challenged with equivocal results that directs towards additional testing for definitive diagnosis and, better patient outcome. The most used therapy for advanced breast cancers is based on the use of AR antagonists, such as bicalutamide and enzalutamide, first- and second-generation AR antagonists respectively. Gene signatures, bioinformatics, and other clinical trials are also beneficial for clinician in estimating the benefits expected from adjuvant chemotherapy. KEY WORDS Breast Cancer, Oestrogen Receptor, Androgen Receptor, Triple Negative

Download Full-text

RADI-17. Outcomes for patients with triple negative breast cancer treated with upfront stereotactic radiosurgery for brain metastases

Neuro-Oncology Advances ◽

10.1093/noajnl/vdab071.087 ◽

2021 ◽

Vol 3 (Supplement_3) ◽

pp. iii21-iii21

Author(s):

Ran An ◽

Yan Wang ◽

Fuchenchu Wang ◽

Akshara Singareeka Raghavendra ◽

Chao Gao ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Brain Metastases ◽

Stereotactic Radiosurgery ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Univariate Analysis ◽

Karnofsky Performance Score ◽

Risk Of Death ◽

Metastatic Sites

Abstract Background Triple-negative breast cancer (TNBC) is an aggressive subtype with high propensity of developing brain metastases (BM). Clinical outcomes and prognostic factors after stereotactic radiosurgery (SRS) for BM were not well defined. Methods We identified 57 consecutive TNBC patients (pts) treated with single fraction SRS for BM during 05/2008–04/2018. Overall survival (OS) from BM diagnosis and freedom from BM progression (FFBMP) after initial SRS were evaluated. BM progression was defined as local and/or distant brain failure (LBF, DBF) after SRS. Kaplan-Meier analyses and Cox proportional hazard regression were used to estimate survival outcomes and identify prognostic factors. Results The median time to BM development from TNBC diagnosis was 23.7 months (mo) (range 0.7‒271.1). Median OS was 13.1 mo (95%CI 8.0‒19.5). On univariate analysis, Karnofsky performance score (KPS) >70 (p=0.03), number of BMs <3 (p=0.016), and BM among the first metastatic sites (p=0.04) were associated with longer OS. On multivariate analysis, KPS ≤70 was associated with higher risk of death (HR 3.0, p=0.03). Of 46 pts with adequate imaging follow-up, 29 (63%) had intracranial progression with a median FFBMP of 7.4 mo (95% CI 5.7–12.7). At 12 mo the estimated cumulative DBF rate was 61.1% (95%CI 40.8%–74.4%) and LBF rate was 17.8% (95%CI 2%–31.1%). Number of BMs (≥3 vs <3) was not associated with FFBMP (p=0.7). Of the 29 pts with BM progression, additional radiation therapy (RT) (vs. no RT) was associated with improved survival (21.7 vs. 7.0 mo, p<0.0001). Conclusions TNBC pts with BM treated with SRS had an OS of 13.1 mo and FFBMP of 7.4 mo. Good KPS was an independent prognostic factor for OS. Further studies with more pts or conducted prospectively are needed to better understand and to improve treatment outcomes in this pt population.

Download Full-text